You don't need to be signed in to access information on BMJ Masterclasses, but you can register here to receive updates about other BMJ Group products and services via our Group site.
Home > Physician series > Haematology > 2009 programme
Document Actions

2009 programme

 

0810-0910 REGISTRATION AND REFRESHMENTS
0910-0920 Welcome and introduction by the Chair

Dr Drew Provan
Senior Lecturer in Haematology, Barts & The London School of Medicine & Dentistry, London, and Editor, ABC of Clinical Haematology
0920-1005 Myeloproliferative disorders
This session will present an update on the management of myeloproliferative disorders. The speaker will cover:
  • How the discovery of JAK2 and other mutations has changed our understanding of polycythaemia vera, essential thrombocythaemia, and idiopathic myelofibrosis
  • How this is already altering the diagnosis, classification, and treatment of these chronic haematological malignancies.
Professor Tony Green
Head of Haematology, Cambridge Institute for Medical Research, University of Cambridge, Cambridge
1005-1050 Myeloma
The speaker will discuss updates in the management of patients with multiple myeloma, including:
  • Diagnostic criteria
  • Assessment of prognosis
  • Moving towards risk-adapted therapy
  • The role of the newer agents.
Dr Charles Singer
Consultant Haematologist, Royal United Hospital, Bath
1050-1110 REFRESHMENTS
1110-1155 Lymphoma
This session will outline the major advances that have been made in the management of lymphomas over the past five years, with regard to the development of immunochemotherapy and prognostic stratification and response monitoring, particularly with CT and PET scanning. The speaker will highlight how these advances are making individualised therapy a realistic prospect.

Dr Robert Marcus
Consultant Haematologist, King's College Hospital, London
1155-1240 Myelodysplastic syndromes
The speaker will discuss recent advances in the management of myelodysplastic syndromes, with particular emphasis on:
  • Prognostic subgroups
  • Cytogenetic categories
  • 5q- syndrome
  • DNMT inhibitors and lenalidomide
  • Evolving therapies.
Professor Ghulam Mufti
Professor of Haemato-oncology and Head of Department, King’s College Hospital, King’s College, London
1240-1340 LUNCH
1340-1425 Industry symposium sponsored by Roche 

Roche logo



Management of chronic lymphocytic leukaemia –
the present and the future in the antibody era
This symposium will cover the evolution of treatment options in chronic lymphocytic leukaemia, including the use of the new therapeutic modalities available now and those likely to be used in the future. Emerging new data, first released at the American Society of Hematology annual meeting will also be presented and the speaker will argue the question: “Is rituximab in combination with chemotherapy the new standard of care in chronic lymphocytic leukaemia?”

Dr George Follows
Consultant Haematologist, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge

Dr Adrian Bloor
Consultant Haematologist, The Christie Hospital, Manchester
1425-1510 Anaemia – recent advances in diagnosis and treatment
The speaker will cover recent advances in the management of anaemias with particular emphasis on:
  • Disturbances of iron metabolism
  • Anaemia of chronic diseases
  • Inherited anaemias.
Dr Mark Layton
Consultant Haematologist, Department of Haematology, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London
1510-1530 REFRESHMENTS
1530-1615 Thrombosis and bleeding
This session will help you make decisions based on up to date evidence regarding:
  • Prevention of venous thrombosis in hospitalised patients
  • Duration of anticoagulation after an episode of venous thrombosis
  •  Safe anticoagulant therapy
  • Reversal of anticoagulation
  • Identification of patients with heritable bleeding tendencies and principles of treatment
  • Management of common acquired bleeding disorders.
Dr Trevor Baglin
Consultant Haematologist, Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge
1615-1700 Haematological emergencies
The speaker will cover important issues regarding key haematological emergencies including:
  •  Those affecting the immunocompromised patient, such as neutropenic sepsis, pneumococcal septicaemia and hypogammaglobulinaemia
  • Sickle cell crisis and chest syndrome
  • Spinal cord compression
  • Superior vena cava obstruction
  • Coagulopathies
  • Hyperviscosity and tumour lysis syndromes.
Dr Jim Murray
Consultant Haematologist, University Hospital Birmingham, Queen Elizabeth Medical Centre, Birmingham
1700-1710 SUMMARY AND CLOSING REMARKS

PROGRAMME SUBJECT TO CHANGE

ALL CONTENT HAS BEEN REVIEWED BY THE EDITOR